Flying cars have garnered all the hype over the years, but it's never gotten anywhere. Here's a new startup attempting to do ...

Two months after Allogene abandoned plans for its CAR-T in leukemia, analysts have suggested that fresh phase 1 data in lymphoma show the therapy can “leapfrog” the competition. The biotech ...